GlassScriptPhysician profile
Usha R Kurra
NPI 1689633075
$1,692.91
in general payments reported to CMS, 2019-2025
24 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $195 · 2021: $471 · 2022: $391 · 2023: $276 · 2024: $78.27 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $591.76 | 2019-2023 | |
| Amgen INC. | $197.38 | 2020-2023 | Tavneos |
| Mayne Pharma Commercial LLC | $155.62 | 2021-2025 | |
| Astellas Pharma US INC | $133.06 | 2019-2025 | Veozah |
| Lilly USA, LLC | $92.79 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $65.33 | 2019-2020 | |
| Agile Therapeutics, INC. | $46.97 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $45.09 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.05 | 2021-2022 | |
| Exeltis, USA INC. | $39.99 | 2021-2022 | |
| Urovant Sciences INC | $31.57 | 2022 | |
| Organon LLC | $31.39 | 2022-2023 | Nexplanon |
| Sumitomo Pharma America, INC. | $31.32 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $26.24 | 2019-2021 | |
| Duchesnay USA Incorporated | $20.31 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.13 | 2022 | |
| Exact Sciences Corporation | $19.11 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $18.13 | 2020 | |
| Laborie Medical Technologies Corp. | $16.73 | 2021 | |
| Novo Nordisk INC | $15.11 | 2023 | Wegovy, Saxenda |
| Avion Pharmaceuticals | $14.21 | 2021 | |
| Dexcom, INC. | $13.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.90 | 2022 | |
| Lupin INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Kurra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.